Organoid Service

Lung Organoid

4929€+
Home » Search Results for 'Lung Organoid'

Lung Organoid

  • Lung alveolar organoids mimic the complex structure of alveoli, providing a realistic model for studying respiratory physiology and diseases.
  • They allow for the study of lung diseases such as pulmonary fibrosis and respiratory infections in a controlled laboratory setting.
  • We've refined our differentiation methods to better replicate the human heart, achieving a precise balanceof myocardialand non-myocardial cells for more mature organoid functions.

Price
4929€+
Organism
Human
Product Type
Adult lung tissue-derived organoid, iPSC-derived organoid
Tissue
Lung
Disease

Applications

Toxicity

Organoid Based

Anti-Virus

Influenza Virus

Adenovirus

Disease Modeling

Respiratory and ENT Disease

Professor Lee Chang-seok Eulji University
Customer insight

Advancing K-Beauty with Skin Organoids: A Next-Generation Platform for Non-Animal Testing and High-Precision Cosmetic Innovation

With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have...

Tomocube (Spatial)
Customer insight

HT-X1: A Label-Free Imaging Breakthrough for Organoid-Based Disease Modeling and Drug Screening

Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...

Seoul National University College of Medicine
Customer insight

Pioneering Spatial Protein Analysis in Korea: Advancing Clinical Pathology with Lambda Biologics’ Support

Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...

K Research Institute
Customer insight

ODISEI-Gut Platform Reveals Immune-Boosting Potential of Kimchi-Derived Bacterial Strain

Among the many fermented foods we consume, kimchi is particularly known for containing a diverse range of lactic acid bacteria, which are believed to influence the activation of immune cells...

Bundang Jesaeng General Hospital
Customer insight

Multiplex Marker Analysis Enhances Research Efficiency with 31-Marker Detection on a Single Slide

We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...

Description

Generation process of human lung organoid

Tissue-Derived Lung Organoids

Tissue-derived lung organoids are cultured from cells directly obtained from patient lung tissue or biopsy samples, allowing them to closely mimic the cellular composition and microenvironment of the original lung tissue. Because they preserve the genetic expression profile and cell-to-cell interactions of the native tissue, they excel at replicating individual patient physiology. This high degree of similarity to human lungs makes them invaluable for personalized therapy development and disease modeling, offering superior physiological relevance compared to traditional 2D cell cultures or animal models.

iPSC-Derived Lung Organoids
Lung organoids derived from induced pluripotent stem cells (iPSCs) recapitulate early embryonic development and can differentiate into mature lung cells and structures. By leveraging iPSC technology, researchers can generate lung cells with specific genetic backgrounds in large quantities, enabling the creation of models that reflect various environmental factors and genetic variations. Moreover, iPSC-derived lung organoids retain stem cell properties while accurately modeling the morphological and functional characteristics of human lungs. This makes them highly suitable for long-term studies, drug screening, and patient-specific therapeutic applications in regenerative medicine.

Cellular and structural similarity

Structural characteristics of lung organoids

Our lung organoids closely mimic the key structural features of human lung tissue.
Replicating the morphology of actual lung tissue, including critical structures like alveoli.
Composed of various cell types, including type I and II alveolar epithelial cells, ciliated cells, and secretory cells, accurately reflecting the functional complexity of real lung tissue.

Expression markers
  • SFTPC Type II pneumocytes
  • AQP5 Bronchial epithelial cells
  • AGER Epithelial cells
  • TP63 Lung epithelial cells
  • SCGB Mucous cells, Respiratory tissue cells
  • MUC5 Mucous cells
  • FOXJ Mucous cells
Structural characteristics of  lung organoids

This compound selectively binds to superoxide, a major marker of oxidative stress produced in the mitochondria. After CCCP treatment, the expression of MitoSOX was increased, indicating an elevation in mitochondrial oxidative stress. This supports the notion that mitochondrial dysfunction plays a critical role in Parkinson’s disease.

Lung influenza model

After infecting PSC-derived lung organoids with H1N1 and H3N2 influenza viruses and treating them with candidate drugs at different concentrations (25, 50, 100, 200 µM), RT-PCR analysis revealed a dose-dependent reduction in viral RNA copy numbers. Notably, a significant decrease in viral RNA copy numbers was observed in the candidate drug-treated groups for both H1N1 and H3N2 influenza, suggesting that these candidate drugs may effectively inhibit influenza virus replication.

PSC-derived Lung organoid
Influenza virus infection
PT-PCR (virus)

Lung fibrosis model

Tissue-derived Lung organoid

In the tissue-derived lung organoids with fibrosis induced by TGF-β, immunohistochemical analysis revealed that Nintedanib treatment led to a reduction in the expression of fibrosis markers, A-SMA and Vimentin, confirming its antifibrotic effect. Similar trends were observed in some candidate drug groups, with certain candidates showing a significant decrease in fibrosis marker expression, suggesting potential antifibrotic effects. These findings indicate that Nintedanib and specific candidate drugs may have potential as therapeutic agents for pulmonary fibrosis.

Connect with Us